Coriolis Pharma expands facilities for ATMP development
The expansion close to company's Martinsried headquarters includes a lyophilisation development centre for advanced therapy medicinal products
Formulation research and development specialist Coriolis Pharma has announced that it is expanding its advanced therapy medicinal products (ATMPs) development facilities.
The company says the expansion at an existing building near its headquarters in Martinsried, Germany -- which began in March this year -- will increase total floor space to 7,800 m2 and will enable its new biosafety level S2 (BSL-2) labs to provide formulation development of ATMPs, cell culture activities, particle characterization and identification, analytical ultracentrifugation and, a lyophilisation development center for ATMPs.
Back in 2018, Coriolis Pharma started strengthening its ATMP capabilities in anticipation of expected growth in the sector.
Although ATMPs are experiencing significant growth, ATMP formulations, however, are far from advanced, largely due to their short shelf life (hours to days) or their requirement for ultracold storage conditions.
To further support the laboratory expansion Coriolis Pharma also expanded its scientific advisory board with Prof. Ernst Wagner from the Ludwig-Maximilians-Universität (LMU) Munich and Prof. Gideon Kersten from Leiden University.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.